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1. Introduction 
Although organ and tissue transplantation has been a fantasy for centuries, the epidemic of 
discovery in transplantation has taken place primarily during the past 55 years. In 1954, Dr 
J. Murray was presented with the unique opportunity to transplant a human kidney 
between identical twins without facing the challenges of acute or chronic allograft rejection 
as well as side effects of long-term immunosuppression (1, 2). Adding to scientific 
knowledge through basic research helped us to perform complex vascularized composite 
allotransplants (VCA) like the hand and face today and vascularized tissues recovered from 
a different individual will soon be extended to all reconstructive transplant procedures 
currently requiring autologous tissues (3-5).  
The development of novel surgical techniques and the discovery of potent 
immunosuppressive drugs in the second half of the 20th century propelled the clinical 
development of organ transplantation(6). The combination of corticosteroids and 
azathioprine, which was the primary immunosuppressive regimen, used from the late 
1960’s until 1980 culminated in one-year survival rates of only 40% - 50%. Most notably, the 
discovery of cyclosporine A and tacrolimus in the 1970’s and 1980’s represented another 
major milestone in solid organ transplantation resulting in excellent short-term and 
acceptable long-term survival rates. With current immunosuppressive regimens mainly 
consisting of the triple combination of corticosteroids, mycophenolate mofetil, and 
tacrolimus the overall graft and patient survival has improved substantially and reached 
one-year graft survival rates of 80%-95% leading to consider organ and tissue 
transplantation as treatment modality of choice for patients with end–stage organ failure or 
severe tissue defects due to trauma or burn. Despite significant improvements in acute 
rejection rates, long-term solid organ allograft survival remained unchanged for the last 15 
years (7). The major causes for late graft loss include chronic allograft rejection and death 
with a functioning graft (8, 9). 
Since the immunologic graft-loss-rate seemed to be highest within the first months after 
transplantation, it became the rule that heightened immunosuppression is required early, 
with progressive reduction over time, leading to the definition of three distinct periods of 
immunosuppression after transplantation: The perioperative “induction period”, where 
immunosuppressants are initially given at high doses, the “early maintenance period”, 
which is characterized by progressive taper of the individual drugs, and the “chronic 
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maintenance period”, characterized by the combination of different immunosuppressants 
used at their lowest effective doses.  
At the end of 20th century, vascularized composite allotransplantation (VCA) like the hand 
and face has been performed in humans with success using the same immunosuppressive 
medications and therapeutic principles used for solid organ transplantation (10). However, 
since hand and face transplants must be considered as non life-saving operative procedures, 
novel immunosuppressive treatment protocols for these types of transplants must be 
developed not only to minimize graft rejection, but also to avoid complications related to 
adverse effects. Several challenges seem to impede the pharmaceutical industry in bringing 
novel immunosuppressive agents to the clinic. However, new powerful 
immunosuppressants are urgently in demand to enable the transplantation of highly 
immunogenic tissues like the skin and at the same time reduce the incidence of drug-
induced toxicity. This goal can only be achieved by either combining synergistic 
immunosuppressive medications to maximize efficacy and minimize toxicity or by 
developing minimization protocols where conventional immunosuppression is tapered or 
even withdrawn shortly after transplantation. 
2. Maintenance immunosuppression regimens 
Maintenance immunosuppression remains the mainstay of therapy for successful outcomes 
after solid organ transplantation. Over the past decades, immunosuppressive regimens tried 
to target multiple immune pathways aiming to decrease acute and chronic allograft rejection 
and maintain long–term graft survival. Although current maintenance therapy after solid 
organ transplantation typically includes calcineurin inhibitors, antimetabolites, and 
corticosteroids, newer therapeutic options including induction therapy with biological 
agents, mTOR inhibitors, and cellular based therapies have emerged as alternative 
immunosuppressive strategies. The following paragraph will discuss immunosuppressants 
that are currently employed in solid organ transplantation. 
2.1 Calcineurin-Inhibitors – Backbone of current immunosuppressive regimens 
Cyclosporine A 
The discovery of cyclosporine A (CsA) still has to be considered as one of the most 
important breakthroughs in transplantation medicine. CsA was initially discovered in 1968 
as a product of Tolypocladium inflatum gams and isolated from the soil of the Norwegian 
plain of Hardanger Vidda (11, 12). At the same time, it was retrieved from fungi imperfecti 
native to Wisconsin. Almost a decade later, in 1976, Jean-Francois Borel described the 
immunosuppressive effects for the first time and hence, the first clinical use in a cadaveric 
kidney transplantation was reported two years later in 1978. Since then, CsA represents the 
backbone of a multitude of maintenance immunosuppressive protocols used in solid organ 
transplantation.   
The immunosuppressive effects of CsA are based on the inhibition of proliferating CD4+ T 
cells by interfering with the IL-2 pathway. In other words, CsA was observed to form a 
complex with cyclophilin that furthermore engages the calcium/calmodulin dependent 
protein phosphatase calcineurin, which in a further step activates “the nuclear factor of 
activated T cells” (NFAT) in cell nucleoli to ultimately upregulate interleukin-2 (IL-2) 
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expression. Based on this IL-2 inhibiton, CsA halts T cell growth and T cell differentiation 
and thereby acts immunosuppressive (13). 
Tacrolimus  
Since the early 1990’s, tacrolimus (FK 506), a macrolide antibiotic, which has been isolated 
from Streptomyces tsukubaensis, represents a mainstay in immunosuppression. Similar to 
CsA, tacrolimus blocks T cell activation and proliferation by interfering with the IL-2 
pathway. FK 506 has been shown to bind the FK-binding protein 12 (FKBP12), which 
ultimately results in the inhibition of the calcineurin pathway leading to decreased IL-2 
mediated T cell proliferation. The binding potency of FK 506 is 10 to 100 times stronger 
when compared to CsA, which results in decreased dosage demand by nonetheless 
retaining it’s immunosuppressive capacity (14, 15). 
Tacrolimus and cyclosporine A have both similar interactions with other medications, 
because of their common metabolism occurring in the liver by the cytochrome P–450 family. 
In addition, they also have a similar side effect profile such as acute and chronic renal 
insufficiency, dyslipidemia, hypertension, electrolyte disturbances, and post transplant 
diabetes. Furthermore, tacrolimus is more strongly associated with neurological 
complications including, seizures, headaches, and tremors. 
2.2 Mycophenolate mofetil – A powerful substitute for azathioprine in antiproliferative 
immunosuppressive therapy 
Mycophenolate Mofetil (MMF) is an antimetabolite immunosuppressant whose active 
component, mycophenolic acid (MPA), inhibits the key enzyme in the purine synthesis 
pathway, inosine monophosphate dehydrogenase (16). The discovery of this 
antiproliferative agent dates back to 1896, when it was first isolated from cultures of 
Penicillium brevicompactum. Initial analyses and studies to proof the immunosuppressive 
competence of MMF were conducted in the early 1980’s. MMF has been shown to inhibit B 
and T cells proliferation, and induce apoptosis of activated T cells. It furthermore limits the 
expression of adhesion molecules on lymphocytes, which results in a decrease of nitric oxide 
production and hence, decreases the recruitment of inflammatory cells (17). Nevertheless, it 
took 15 more years until the Food and Drug Administration (FDA) approved this drug for 
the prevention of renal allograft rejection in 1995 (18). 
Several clinical trials in the recent past pointed out that the combination of MMF with 
calcineurin inhibitors results in enhanced patient and graft survival and reduces events of 
acute and chronic rejection (19). MMF furthermore might be an alternative drug for patients 
developing drug-induced nephrotoxicity due to other immunosuppressive treatment (20). 
Besides bone marrow suppression and subsequent leucopenia, diarrhea, and GI distress are 
the most notable side effects of this immunosuppressant. However, recently a new “ enteric 
coated” formulation of MMF has been developed, which has been shown to improve the 
mycophenolate exposure and hence, decreases GI side effects. In addition, MMF replaced 
azathioprine after 5 decades of its successful utilization as an antiproliferative 
immunosuppressive agent in the area of solid organ transplantation. 
2.3 Azathioprine 
Azathioprine has a long history of use in the field of solid organ transplantation (21). As an 
antimetabolite, azathioprine exerts its immunosuppressive properties by halting DNA 
replication of T and B cells, as well as by interfering with costimulatory signals, which 
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ultimately results in lymphocyte depletion (22). Before the discovery of CsA, the 
combination of azathioprine and steroids represented the standard treatment of choice in 
solid organ transplantation, however, like most immunosuppressive agents, azathioprine 
has multiple drug interactions and side effects. If co-administered with allopurinol for the 
treatment of gout or hyperuricemia due to a decrease in drug metabolism of both agents, 
azathioprine should only be dosed at 20% to 30% of normal dosage (23). The main toxicity 
associated with azathioprine is a dose dependent myelosuppression resulting in leucopenia, 
thrombocytopenia, and macrocytic anemia. Additionally, hepatotoxcicity and an increased 
incidence in malignancies have been reported. Today, azathioprine has widely been 
replaced by mycophenolate mofetil.  
2.4 mTOR-Inhibitors 
Another powerful class of immunosuppressive drugs comprises inhibitors of the 
mammalian target of rapamycin (mTOR), a key signaling kinase that affects broad aspects of 
cellular function like cell growth, as well as protein synthesis, and transcription (24, 25). The 
first mTOR inhibiting substance, sirolimus (Rapamycin), was isolated from soil obtained on 
Easter Island (Rapa Nui) and was initially identified as a potent antifungal metabolite (26).  
However, this macrolide produced by Streptomyces hygroscopicus also turned out to inhibit 
cell proliferation and thereby produced antitumor and immunosuppressive activity. Finally, 
in 1999 sirolimus got its FDA approval for the prevention of kidney allograft rejection. 
Initially, the implementation of sirolimus was supposed to potentiate the therapy with CsA, 
but the combination controversially increased nephrotoxicity, hypertension, as well as the 
incidence of hemolytic-uremic syndrome. Hence, a controlled trial in kidney transplantation 
confirmed increased nephrotoxicity and hypertension in the treatment group of sirolimus 
combined with tacrolimus, which has been compared to the combined use of 
mycophenolate mofetil and tacrolimus.  
The synthetic derivate of sirolimus, everolimus, showed an increased bioavailability, but 
there were no affects in interaction with CsA compared to sirolimus observed. Severe side 
effects of both lipophilic macrolides have been reported including hyperlipidemia, 
thrombocytopenia, aggravation of proteinuria, mouth ulcers, skin lesions, as well as 
pneumonitis, and impaired wound healing (27). Especially in kidney grafts, delayed 
recovery from acute tubular necrosis was observed. 
2.5 Corticosteroids 
From the early beginnings of solid organ transplantation, corticosteroids have played a key 
role in maintenance immunosuppression as well as treatment of acute rejection episodes. 
Today, most immunosuppressive protocols contain high doses of methylprednisolone 
perioperatively with a subsequent tapering to approximately 5 to 7.5mg per day over the 
ensuing months.  
Although it has been shown that corticosteroids have anti-inflammatory and 
immunosuppressive properties due to their suppression of prostaglandin synthesis, their 
stabilization of lysosomal membranes, and subsequently their reduction of histamine and 
bradykinin, the exact mechanism of action remains incompletely understood (18). 
Experimental data provide evidence that a continuous corticosteroid treatment due to the 
presence of glucocorticoid receptors on T cells, results in steroid mediated T regulatory 
FOXP3 expression and thus suppressor activity (28, 29).  
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In addition to their therapeutic immunosuppressive effects, corticosteroids have several 
severe side effects, especially when administered for a long time, which limit their 
applicability in post-transplant therapy (30). These sequels include inter alia: diabetes, 
hypertension, obesity, cushingoid features, osteoporosis, poor wound heeling, and adrenal 
suppression (31). However, despite many transplant clinicians search out steroid-sparing or 
even steroid–free regimens due to their deleterious side effects, especially induction therapy 
regimens still continue to include steroids in their treatment regimens. 
3. Induction therapy 
Many transplant centers in the United States and Europe are currently preferring to apply 
intense therapy at the time of transplantation with the goal to deplete the recipient’s 
immune system in the immediate post-transplant period to decrease early deleterious 
interactions between the recipient’s immune system and the donor allograft to ultimately 
induce a tolerogenic state (32). It has been widely accepted that early alloreactivity not only 
leads to an increase in acute rejection episodes, but also promotes chronic rejection which 
ultimately leads to poor long–term graft survival. While current induction 
immunosuppression agents have reduced the incidence of acute rejection, the goal of 
transplant tolerance has not been realized. 
3.1 Antibodies 
OKT3 
Antibody mediated immunosuppressants have been used as induction therapy to suppress 
the recipient’s immune system immediately after transplantation. There are both, polyclonal 
as well as monoclonal, antibodies available. OKT3 is a murine monoclonal antibody, which 
targets the T cell receptor CD3 complex resulting in a decrease of T cell activation (33). As a 
side effect OKT3 treatment commonly causes a “cytokine release syndrom” with fevers, 
chills, headaches and myalgias. As a consequence, patients are premedicated with steroids, 
acetaminophen, and diphenhydramine as a prophylaxis against this inflammatory response. 
Other less frequent side effects include pulmonary edema, seizures, aseptic meningitis, and 
renal insufficiency (34). 
Basiliximab (Simulect) 
Basiliximab is another antibody, commonly used as an induction agent, which interferes 
with the alpha subunit (CD25) of the IL-2 receptor (35). This monoclonal antibody of 
chimeric human-murine origin formidably decreases T cell proliferation and differentiation 
without T cell depletion. It is preferentially used in patients with the risk of low to moderate 
rejection episodes and it’s currently approved for dosing 20mg on the first and fourth day 
after transplant (36). Being humanized, there were only minimal toxic effects reported, 
although basiliximab has been associated with pulmonary edema and ARDS-like symptoms 
(37). 
Alemtuzumab (Campath) 
Alemtuzumab is a humanized-rat monoclonal antibody directed against CD52, which is 
present on the surface of mature lymphocytes (38). Originally prescribed in lymphocytic 
leukemia and lymphoma, alemtuzumab is currently also used as a potent induction agent in 
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solid organ and vascularized composite allografts. Although the function of CD52 remains 
incompletely understood, it is present on the cell surface of B and T cells, as well as 
macrophages, and NK cells which get depleted upon binding of alemtuzumab. Although 
alemtuzumab has a half-life of about 2 weeks, different cells have different rates of recovery 
after therapy. Additionally, alemtuzumab has been shown to deplete T cells 
inhomogenously, with a relative sparing of memory T cells and T regulatory cells. In terms 
of side effects, alemtuzumab has been associated with neutropenia, anemia, pancytopenia, 
first-dose reactions, and autoimmunity (37). 
Antithymocyte Globulin  
Anthithymocyte globulin (ATG) is a polyclonal antibody derived from animals that have 
been immunized with human lymphocytes. As a result, ATG is nonspecifically directed 
against human lymphocytes, which upon treatment get depleted through multiple 
mechanisms including complement-mediated lysis and opsonisation. In addition, ATG 
might induce alloantigen specific immunological tolerance as ATG binds lymphocyte 
costimulatory molecules and similar to OKT3 and alemtuzumab expands T regulatory cells 
in vitro and in vivo (39). Polyclonal antithymocyte globulin is preferrably used as an agent in 
steroid-free regimes due to its positive effects in the treatment of steroid-resistant rejection 
episodes. However, ATG treatment frequently induces an acute reaction to initial 
administration consisting of fever, rigors and anaphylaxis with some patients developing 
leucopenia and thrombocytopenia. 
3.2 Fusion proteins 
CTLA4-Ig (Abatacept, Belatacept) 
Full T cell activation depends on two signals. The first signal is generated upon MHC- 
antigen - T cell receptor (TCR) interaction. The costimulation pathway, or signal two, is 
activated when accessory molecules bind to their ligands. Specifically the CD28/B7 pathway 
(CD80 and CD86) has proven itself to be relevant for sustained naïve T cell activation. 
Interfering with these pathways has been one of the most intensively investigated areas in 
immunology, particularly when considering therapeutic interventions. 
After 25 years of research, the fusion receptor protein CTLA4-Ig (abatacept), a competitive 
antagonist for CD80/CD86 binding, was finally approved for the therapy of rheumatoid 
arthritis. For the specific use in solid organ transplantation, where an even more robust 
immunosuppression is required, a second-generation fusion protein called belatacept was 
developed. Belatacept has proven efficient in prolonging renal allograft survival alone or in 
combination therapies with basiliximab or MMF and prednisone (40).  
3.3 Immunosuppression in Vascularized Composite Allotransplantation  
Immunosuppression in vascularized composite allotransplantation (VCA) remains a 
difficult issue, since the treatment with conventional immunosuppression used in solid 
organ transplantation is associated with life–threatening infectious complications (41) and 
metabolic side effects, which seem to be intolerable for non life-saving procedures like hand 
and face transplantation (42, 43). As a consequence, reconstructive surgeons and 
immunologists more than ever seek to establish stable donor antigen specific immunological 
tolerance to vascularized composite allografts, a state that impairs the immune system not to 
mount responses against a specific allograft, but at the same time facilitates natural defenses  
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Fig. 1. Immunosuppressive drugs currently used in solid organ transplantation 
against viral and bacterial infections. However, in the early days of reconstructive 
transplantation, immunosuppressive regimens consisted of initial high–dose induction 
therapy, mainly ATG, or alemtuzumab, which in most cases was followed by a conventional 
triple combination of corticosteroids, calcineurin inhibitors, and mycophenolate mofetil (44). 
Exceptions to this conventional immunosuppressive treatment include some recent cases in 
hand transplantation, where patients received induction therapy with alemtuzumab 
followed by maintenance immunosuppression with tacrolimus and mycophenolate mofetil 
(Louisville) or tacrolimus and prednisone (Innsbruck). More recently, the “Pittsburgh 
Protocol” consisting of an induction therapy with alemtuzumab and a donor specific 
bonemarrow cell transfusion within 2 weeks after transplantation proofed that maintenance 
immunosuppression with tacrolimus alone can successfully be achieved in VCA. The idea of 
donor cell infusion for either the induction of chimerism or the intensification of clonal 
exhaustion or deletion of alloreactive T cells is appealing, however, the combination of such 
a concept with high–dose multi drug immunosuppression might be counterproductive, 
because such phenomena may require the persistence of a certain degree of immune 
response to be effective. Recent innovative immunosuppressive protocols proofed to be 
effective in weaning patients off immunosuppression or at least in allowing a reduction of 
immunosuppression to a minimum level (45, 46). Nevertheless, from the current clinical 
point of view in reconstructive transplantation, it is difficult to conclude the superiority 
from one immunosuppressive regimen over another and it seems mandatory to pursue 
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multicenter prospective trials despite the limited number of patients that are currently 
eligible to be enrolled in such trials. 
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biomedical literature, largely in specialized journals. This book will serve well the practicing physicians,
surgeons and biomedical scientists as it provides an insight into various approaches to immunosuppression
and reviews current developments in each area.
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